Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes
View abstract on PubMed
Summary
This summary is machine-generated.Molecular classification improves endometrial cancer treatment by identifying tumor subtypes. However, Latin America faces challenges in accessing advanced diagnostics and therapies for precision medicine.
Area Of Science
- Oncology
- Genomics
- Pathology
Background
- Molecular characterization enhances understanding of endometrial cancer.
- Molecular classification offers superior reproducibility and prognostic value over histological methods.
- The Proactive Molecular Risk Classifier aligns with Cancer Genome Atlas Research Network classifications.
Purpose Of The Study
- To discuss the transition to precision medicine in endometrial cancer treatment.
- To highlight challenges in implementing international guidelines in Latin America.
- To propose solutions for improving endometrial cancer care in the region.
Main Methods
- Review of molecular classification systems for endometrial cancer.
- Analysis of the impact of molecular profiling on treatment strategies.
- Discussion of healthcare system barriers in Latin America.
Main Results
- Molecular classification, including DNA polymerase epsilon-mutated, mismatch repair-deficient, p53 abnormal, and non-specific molecular profiles, is crucial.
- The shift towards targeted agents and immunotherapy requires specialized pathology and novel agents.
- Significant barriers hinder the implementation of advanced endometrial cancer care in Latin America.
Conclusions
- Precision medicine is emerging for endometrial cancer, necessitating advanced pathology and treatments.
- Continued efforts are essential to overcome regional disparities in endometrial cancer care.
- Addressing challenges in Latin America is key to equitable access to improved endometrial cancer therapies.

